Empery Asset Management LP recently announced the acquisition of new stake in Allena Pharmaceuticals Inc. (NASDAQ:ALNA). This fresh investment now brings its stake to 7.33% valued currently at $3.46 million. In addition, Sabby Capital LLC raised its holdings by 1.53 million to 1.53 million shares. And BBVA Asset Management SA SGIIC has lifted its position by 113.31% or 0.4 million shares – to 0.75 million shares.
With over 1.08 million Allena Pharmaceuticals Inc. (ALNA) shares trading Friday and a closing price of $1.38 on the day, the dollar volume was approximately $1.48 million. The shares have shown a negative weekly performance of -10.39% and its price on 08/21/20 lost nearly -2.13%. Currently, there are 37.95M common shares owned by the public and among those 27.66M shares have been available to trade.
An analysis of what Wall Street brokers have to say about the expected price targets for this stock gives us this picture: 7 analysts who have offered their price forecasts for ALNA have a consensus price objective of $9.00. The analysts have set the share’s price value over the next 12 months at a high of $26.00 and a low of $1.00 should the stock experience a downside. Incidentally, analysts’ outlook for the Allena Pharmaceuticals Inc. stock is 1.70 for the next 12 months. But an upside of 94.69% will see the stock hit the forecast high price target while mean target price for the stock is $6.50.
Insiders at the company have transacted a total of 0 times over the past 12 months, according to data filed with the U.S. Securities and Exchange Commission (SEC). 0 of these insider trades were purchases, accounting for 0 shares. Insider sales of the common stock occurred on 0 occasions, with total insider shares sold totaling 0 shares.
The top 3 mutual fund holders in Allena Pharmaceuticals Inc. are Vifag 2002, SICAV, FCP Medical – BioHealth, and Vanguard Total Stock Market Index. Vifag 2002, SICAV owns 0.7 million shares of the company’s stock, all valued at over $0.87 million. The company bought an additional 0.35 million shares recently to bring their total holdings to about 1.83% of the shares outstanding. FCP Medical – BioHealth bought 0.28 million shares to see its total holdings expand to 0.39 million shares valued at over $0.48 million and representing 1.02% of the shares outstanding. Vanguard Total Stock Market Index now owns shares totaling to 0.64% of the shares outstanding.
Shares of Allena Pharmaceuticals Inc. (NASDAQ: ALNA) opened at $1.42, up $0.01 from a prior closing price of $1.41. However, the script later closed the day at $1.38, down -2.13%. The company’s stock has a 5-day price change of -10.39% and -26.60% over the past three months. ALNA shares are trading -49.45% year to date (YTD), with the 12-month market performance down to -68.42% lower. It has a 12-month low price of $0.52 and touched a high of $6.30 over the same period. Currently, 1.08 million shares have been traded, compared to an average intraday trading volume of 1.48 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -2.85%, -10.51%, and -26.10% respectively.
Institutional ownership of Allena Pharmaceuticals Inc. (NASDAQ: ALNA) shares accounts for 45.60% of the company’s 37.95M shares outstanding. Mutual fund holders own 30.51%, while other institutional holders and individual stakeholders account for 5.63% and 22.86% respectively.
It has a market capitalization of $53.70M. The earnings-per-share (ttm) stands at -$1.62. Price movements for the stock have been influenced by the stock’s volatility, which stands at 8.05% over the week and 9.05% over the month.
Analysts forecast that Allena Pharmaceuticals Inc. (ALNA) will achieve an EPS of -$0.22 for the current quarter, -$0.21 for the next quarter and -$0.88 for 2021. The lowest estimate earnings-per-share for the quarter is -$0.26 while analysts give the company a high EPS estimate of -$0.18. Comparatively, EPS for the current quarter was -$0.57 a year ago. Earnings per share for the fiscal year are expected to decrease by -24.20%, and 6.40% over the next financial year.
If you are looking to buy this stock, then you may note that the average analyst recommendation by 7 brokerage firm advisors rate Allena Pharmaceuticals Inc. (ALNA) as a “Strong Buy” at a consensus score of 1.70. Specifically, 6 Wall Street analysts polled rate the stock as a buy, while 1 of the 7 advise that investors “hold,” and 0 rated it as a “Sell.”
Looking at the support for the ALNA, a number of firms have released research notes about the stock. H.C. Wainwright stated their Buy rating for the stock in a research note on June 01, 2020, with the firm’s price target at $10. Credit Suisse coverage for the Allena Pharmaceuticals Inc. (ALNA) stock in a research note released on July 10, 2019 offered a Outperform rating with a price target of. Robert W. Baird was of a view on January 18, 2019 that the stock is Outperform, while B. Riley FBR gave the stock Buy rating on December 21, 2018, issuing a price target of. Jefferies on their part issued Buy rating on November 08, 2018.